YG
Yubiao Guo

Highly Cited

125
Works
2,606
Citations
23
H-Index
Search Authors
Author Statistics
External Links
OpenAlex Profile ORCID Profile

Yubiao Guo

Also known as: Guo Y, Y Guo, Y. B. Guo, Y. Guo, Yu-Biao Guo

125

Total Works

2,606

Citations

23

H-Index

45

i10-Index

Citation & Works Trend by Year
24 years active
Top Research Topics
Asthma and respiratory diseases (38) Lung Cancer Treatments and Mutations (28) Lung Cancer Diagnosis and Treatment (25) Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (17) Pleural and Pulmonary Diseases (17)
Recent Publications
15 shown
Year Publication Title Citations Action
2026 Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer JAMA 6
2026 Crizotinib or vebreltinib response and resistance in advanced non-small cell lung cancer with MET exon 14 skipping Discover Oncology 0
2026 Deulorlatinib (TGRX-326) in ALK Gene Fusion Positive NSCLC After Failure of Second-Generation Inhibitors: A Single-Arm, Multicenter, Phase 2 Trial Journal of Thoracic Oncology 0
2026 Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial The Lancet 28
2025 Safety, pharmacokinetic, pharmacodynamic, and efficacy properties of orally administered APG-2449 in patients with advanced ALK and ROS1 non-small-cell lung cancer: a multicentre, open-label, single-arm phase 1 trial EClinicalMedicine 3
2025 DNAJA1 as a modulator of CD8 + T-cell function and prognosis in lung cancer: implications for immune regulation and therapeutic targeting Journal of drug targeting 0
2025 Construction of a LncRNA Signature-Based Predictive Nomogram for Lung Adenocarcinoma Lung Cancer 0
2025 The relationship between PTPRH and CEACAM5 and Th17 immune response in severe asthma patients. 0
2025 Molecular testing, treatment patterns, and outcomes in EGFR-mutated non-small cell lung cancer: the PISCES study Future Oncology 1
2025 Biomarker and Prognostic Value of Super-ARMS Detection for EGFR Mutation in Advanced NSCLC OncoTargets and Therapy 0
2025 Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and MET -amplification ( MET amp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): Results from a randomized phase 3 SACHI study. Journal of Clinical Oncology 11
2025 657 | TRANSPLANTATION IN COMBINATION WITH CAR‐T THERAPY FOR REFRACTORY/RELAPSED AGGRESSIVE B‐CELL LYMPHOMA AFTER FAILURE OF CD19 CAR‐T CELL THERAPY Hematological Oncology 0
2025 First report of efficacy and safety results from a phase 2 trial evaluating BNT327/PM8002 plus chemotherapy (chemo) as first-line treatment (1L) in unresectable malignant mesothelioma. Journal of Clinical Oncology 5
2025 PMN ‐ MDSCs Orchestrate the Immunosuppressive Microenvironment in the Lung and Are Associated With Clinical Outcome in Bronchiectasis Respirology 3
2025 Mutant p53 confers chemoresistance by activating KMT5B-mediated DNA repair pathway in nasopharyngeal carcinoma Cancer Letters 5

Data source: OpenAlex API